دورية أكاديمية
أعرض في EDS

Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases.

التفاصيل البيبلوغرافية
العنوان: Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases.
المؤلفون: Muynck LDAN; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Gaarenstroom KN; Department of Gynecology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Sier CFM; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Duijvenvoorde MV; Department of Gynecology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Bosse T; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Mieog JSD; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Kroon CD; Department of Gynecology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Peters ITA; Department of Gynecology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
المصدر: Cancers [Cancers (Basel)] 2020 Jun 12; Vol. 12 (6). Date of Electronic Publication: 2020 Jun 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. Intraoperative molecular imaging that targets cell-surface proteins on tumor cells may guide surgeons to detect metastases otherwise not visible to the naked eye. Previously, we identified 29% more metastatic lesions during cytoreductive surgery using OTL-38, a fluorescent tracer targeting folate receptor-a (FRa). Unfortunately, eleven out of thirteen fluorescent lymph nodes were tumor negative. The current study evaluates the suitability of five biomarkers (EGFR, VEGF-A, L1CAM, integrin avb6 and EpCAM) as alternative targets for molecular imaging of EOC metastases and included FRa as a reference. Immunohistochemistry was performed on paraffin-embedded tissue sections of primary ovarian tumors, omental, peritoneal and lymph node metastases from 84 EOC patients. Tumor-negative tissue specimens from these patients were included as controls. EGFR, VEGF-A and L1CAM were highly expressed in tumor-negative tissue, whereas avb6 showed heterogeneous expression in metastases. The expression of EpCAM was most comparable to FRa in metastatic lesions and completely absent in the lymph nodes that were false-positively illuminated with OTL-38 in our previous study. Hence, EpCAM seems to be a promising novel target for intraoperative imaging and may contribute to a more reliable detection of true metastatic EOC lesions.
References: Am J Pathol. 2004 May;164(5):1511-8. (PMID: 15111296)
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:71-87. (PMID: 27884789)
Br J Cancer. 2011 Apr 12;104(8):1241-5. (PMID: 21364581)
Clin Cancer Res. 2016 Jun 15;22(12):2929-38. (PMID: 27306792)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Nat Rev Clin Oncol. 2010 Jul;7(7):381-93. (PMID: 20386556)
Genes Cancer. 2017 May;8(5-6):589-599. (PMID: 28740577)
Lancet Oncol. 2019 Jul;20(7):e354-e367. (PMID: 31267970)
Clin Cancer Res. 2008 May 15;14(10):3030-5. (PMID: 18483368)
Cochrane Database Syst Rev. 2014 Feb 21;(2):CD009786. (PMID: 24563459)
Nat Rev Cancer. 2018 Apr;18(4):211-223. (PMID: 29422598)
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68. (PMID: 29718305)
Gynecol Oncol. 2015 Oct;139(1):5-9. (PMID: 26196319)
Gynecol Oncol. 2014 Jun;133(3):401-4. (PMID: 24878391)
Gynecol Oncol. 2016 Oct;143(1):3-15. (PMID: 27650684)
Gynecol Oncol. 2017 Feb;144(2):266-273. (PMID: 27916269)
Gynecol Oncol. 2017 Sep;146(3):449-456. (PMID: 28645428)
J Gynecol Oncol. 2014 Jul;25(3):221-8. (PMID: 25045435)
J Natl Cancer Inst. 2010 Jul 7;102(13):982-7. (PMID: 20445161)
J Clin Pathol. 2011 May;64(5):415-20. (PMID: 21415054)
South Asian J Cancer. 2013 Apr;2(2):87-90. (PMID: 24455566)
Nat Rev Clin Oncol. 2013 Sep;10(9):507-18. (PMID: 23881033)
Oncotarget. 2017 Jul 4;8(27):44312-44325. (PMID: 28574829)
Cancer. 2009 Mar 15;115(6):1234-44. (PMID: 19189349)
Curr Drug Targets. 2009 Jul;10(7):645-52. (PMID: 19601768)
Gynecol Oncol. 2013 Jul;130(1):192-9. (PMID: 23558051)
Adv Cancer Res. 2014;124:171-211. (PMID: 25287689)
Ann Oncol. 2012 Jul;23(7):1795-802. (PMID: 22228447)
Nat Med. 2011 Sep 18;17(10):1315-9. (PMID: 21926976)
Ann Oncol. 2017 Nov 1;28(suppl_8):viii16-viii24. (PMID: 29232470)
Cell Oncol (Dordr). 2012 Feb;35(1):9-18. (PMID: 21647742)
Cancer Biol Med. 2017 Feb;14(1):9-32. (PMID: 28443200)
معلومات مُعتمدة: N/A Stichting Zabawas; 91619059 Nederlandse Organisatie voor Wetenschappelijk Onderzoek; UL2015-8089 KWF Kankerbestrijding
فهرسة مساهمة: Keywords: biomarkers; epithelial ovarian cancer metastases; near-infrared fluorescence; surgery; tumor-targeted molecular imaging
تواريخ الأحداث: Date Created: 20200618 Latest Revision: 20200928
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7352913
DOI: 10.3390/cancers12061562
PMID: 32545676
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers12061562